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Abstract
Background: Blood sugar metabolism abnormalities have been identified in HIV-infected individuals and associated with
HIV-associated neurocognitive disorders (HAND). These abnormalities may occur as a result of chronic HIV infection, long-
term use of combined antiretroviral treatment (CART), aging, genetic predisposition, or a combination of these factors, and
may increase morbidity and mortality in this population.
Objective: To determine if changes in soluble and cell-associated insulin receptor (IR) levels, IR substrate-1 (IRS-1) levels, and
IRS-1 tyrosine phosphorylation are associated with the presence and severity of HAND in a cohort of HIV-seropositive
women.
Methods and Results: This is a retrospective cross-sectional study using patient database information and stored samples
from 34 HIV-seropositive women and 10 controls without history of diabetes from the Hispanic-Latino Longitudinal Cohort
of Women. Soluble IR subunits [sIR, ectodomain (a) and full-length or intact (ab)] were assayed in plasma and CSF samples
by ELISA. Membrane IR levels, IRS-1 levels, and IRS-1 tyrosine phosphorylation were analyzed in CSF white cell pellets (WCP)
using flow cytometry. HIV-seropositive women had significantly increased levels of intact or full-length sIR in plasma
(p,0.001) and CSF (p,0.005) relative to controls. Stratified by HAND, increased levels of full-length sIR in plasma were
associated with the presence (p,0.001) and severity (p,0.005) of HAND. A significant decrease in IRS-1 tyrosine-
phosphorylation in the WCP was also associated with the presence (p,0.02) and severity (p,0.02) of HAND.
Conclusions: This study provides evidence that IR secretion is increased in HIV-seropositive women, and increased IR
secretion is associated with cognitive impairment in these women. Thus, IR dysfunction may have a role in the progression
of HAND and could represent a biomarker for the presence and severity of HAND.
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Introduction
The prevalence of HIV-associated neurocognitive disorders
(HAND) has increased due to the widespread use of combined
antiretroviral treatment (CART) and resulting longer survival of
HIV-infected patients [1,2,3]. In the United States, HAND’s
prevalence among HIV-infected individuals on CART is as high
as 50%, and HAND continues to be a significant cause of
morbidity in chronically infected patients [4,5]. The majority of
these patients suffer from the milder forms of HAND [5,6], which
can develop and progress despite adequate viremia control and
good CART adherence [7,8,9,10,11]. In addition, blood sugar
metabolism abnormalities, such as insulin resistance, have recently
been identified in HIV-infected individuals and associated with
HAND [12,13,14,15]. Studies in the general population indicate
that such abnormalities may precede the overt onset of diabetes by
several years [16,17], and are risk factors for cardiovascular and
cerebrovascular outcomes [18].
Insulin receptor dysfunction may also contribute to cognitive
impairment [19,20,21]. Insulin receptor and the type 1 insulin-like
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neuronal growth and survival, and synaptic plasticity (Reviewed in
[20,22,23,24]). Insulin receptors are enriched in the hippocampus,
and insulin has been shown to enhance learning and memory, and
to promote hippocampal long-term potentiation [24]. Conversely,
insulin resistance and diabetes have been associated with risk of
cognitive impairment and dementia in the general population
[19,25,26,27,28,29] and in patients with HIV [12,13].
While blood glucose abnormalities have been associated with
the development of HAND, no studies to date have evaluated
plasma sIR subunit expression in HAND. Exploring potential
changes in sIR expression in HIV patients could provide insight
into the pathogenesis of HAND.
Changes in plasma sIR expression might also serve as
biomarkers for HAND. Since the advent of CART, the clinical
spectrum of HAND has changed. Whereas several CSF inflam-
matory markers such as beta-2-microglobulin correlated with
HIV-associated dementia (HAD) in the pre-CART era, in CART-
treated individuals these markers show little correlation
[3,9,10,30,31,32,33]. Hence, there is a critical need to identify
alternative biomarkers for HAND, particularly its milder forms.
Several studies are evaluating potential CSF and blood markers,
including inflammatory markers, activated monocytes (CD16+),
proviral HIV DNA, and ‘‘omics’’ profiles. Others are using
neuroimaging methods such as magnetic resonance spectroscopy,
functional MRI, diffusion tensor imaging, or resting cerebral blood
flow [32,34,35,36]. However, CSF sampling is invasive, and
neuroimaging may be impractical or unfeasible in many settings
[37]. Blood biomarkers would be ideal, as these can be most easily
and non-invasively obtained. Plasma full-length sIR could serve as
a blood biomarker for early stages of HAND. In addition, the
effect of insulin resistance on cognition can be reversed by the
administration of insulin [22]. Thus, identification of insulin
resistance in HIV patients could open a treatment modality early
in the course of HAND to lessen its severity and progression. We
therefore performed a retrospective study to evaluate how soluble
and cell-associated insulin receptor dysfunction might correlate
with severity of HAND in HIV-infected women.
Methods
Objective
To determine if changes in soluble and cell-associated insulin
receptor (IR) levels, IR substrate-1 (IRS-1) levels, and IRS-1
tyrosine phosphorylation are associated with the presence and
severity of HAND in a cohort of HIV-seropositive women.
Participants and study design
This is a retrospective cross sectional study using patient
database information and the samples repository of the Hispanic-
Latino Longitudinal Cohort of Women. This study is approved by
the University of Puerto Rico Medical Sciences Campus (UPR
MSC) Institutional Review Board and all participants signed a
written informed consent. This cohort is part of the NeuroAIDS
Specialized Neuroscience Research Program (SNRP) at the UPR,
MSC. This is a unique cohort of Hispanic HIV-seropositive
women characterized longitudinally with viral and immune
profiles, neurological exams, and neuropsychological tests.
Thirty-four (34) HIV-seropositive women and 10 seronegative
controls without history of diabetes were evaluated as described
previously [38]. These participants fulfilled inclusion and exclusion
criteria of the Hispanic-Latino Longitudinal Cohort of Women
(described previously in [38]) with the inclusion criteria of (i) being
$18 years old, (ii) having completed at least a 9
th grade education,
and (iii) having a nadir CD4 cell count #500 cells/mm
3 during the
last year and/or a viral load .1,000 copies/mL while using
HAART. Women with a history of neurodegenerative diseases or
prior CNS infections (e.g., toxoplasmosis), psychiatric conditions,
active infections, or head trauma were excluded. These criteria
identified a group of women with HIV-1 infection who were at risk
of developing HAND [39,40]. The selection of participants did not
rely on self-reported cognitive concerns. Participants underwent
neurological and neuropsychological evaluations, blood sampling
to determine viral immune profiles, and test for hepatitis C virus,
and CSF sampling. The women were matched for age and
education. Fasting blood sugar test (FBS) was normal in the 24
women who had the test performed for other reasons.
HIV-seronegative control samples were 5 plasma samples
obtained from healthy donors and 5 CSF samples from Dr.
Wojna’s CSF repository at the UPR MSC. The CSF samples were
obtained in the course of medical care such as surgical
gynecological procedures where spinal anesthesia was performed,
and in one case from a patient with Acute Demyelinating
Encephalomyelitis (ADEM). The women who underwent spinal
anesthesia were not receiving any medications prior to the spinal
tap. Controls and HIV-seropositive women were matched for age.
Description of Procedures undertaken
Ethics and Participant’s evaluations. After giving their
consent to take part in this IRB-approved research project,
individual participants were required to provide demographic and
medical history information along with having a macroneurolo-
gical exam and specimens for laboratory analysis. The information
included age, most likely mode of HIV transmission, nadir CD4
cell count, and actual antiretroviral treatment. Plasma and CSF
viral load was determined via Ultrasensitive RNA Roche Amplicor
at an AIDS Clinical Trials Group (ACTG)-Certified Laboratory.
Neurocognitive testing. Neurocognitive tests (described
previously in [38,41]) evaluated the following cognitive domains
(neuropsychological [NP] tests/subtests): verbal memory (trial 5,
delay recall, and recognition of a Spanish translation of the Rey
Auditory Verbal Learning Test), frontal executive function (Stroop
Color Word Test [word/color, Manual de Stroop. Copyright
1993, by TEA ediciones, S.A. Madrid (Espan ˜a)] and Trail Making
B), psychomotor speed (Symbol Digit Modalities Test and visual
and auditory reaction time non dominant hand), and motor speed
(Trail Making A and Grooved Pegboard dominant and non
dominant hand). Depressive symptoms were determined using the
Beck Depression Index [42,43]. The cognitive pre-morbid status
between HIV-seropositive and HIV-seronegative women was
determined using the Wechsler Adult Intelligence Test - Vocab-
ulary subtest [44] and the Woodcock-Muniz Test - Reading
subtest (W31) [45]. All tests were conducted in Spanish. We
calculated z-scores for each NP tests/subtests using a reference
control group of 34 HIV-seronegative healthy women that did not
differ from the HIV-seropositive participants with regard to socio-
economic status (mode ,$5,000 annual income), education
(p=0.828), and pre-morbid status (reading and vocabulary
performance, p=0.649 and 0.190 respectively). A significant
difference between reference control group and HIV-seropositive
women was observed in age (p,0.001), where the mean age(SD)
and range of the younger reference control group (n=34) was of
34.2(6.9) years with a range of 22 to 49 years while the HIV+
women (n=34) had 42.1(7.3) years with a range of 25 to 54 years,
and in the Beck’s Depression Index (BDI) where HIV-seropositive
women presented with higher scores of depressive symptoms
(p=0.001). A z-score (using the mean and standard deviation of
the reference control group) was calculated for each test, cognitive
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seropositive women group presented with a mean (SD) in the
following socio-demographic characteristics age of 42.1(7.3) years,
education of 12.7(2) years, and a pre-morbid status in reading of
27.9(2) and vocabulary of 47.6(11.7). Depressive symptoms as
determined by Beck Depression Index of 10.9(9.8).
Cognitive impairment was defined according to the American
Academy of Neurology (AAN) HIV criteria modified to identify
asymptomatic cognitive impairment as described previously
[38,41,46]. Using this scale we grouped the HIV-seropositive
women into 11 with normal cognition, 8 with asymptomatic
neurocognitive impairment, and 15 with symptomatic neurocog-
nitive impairment (mild cognitive motor disorder [MCMD, n=1]
and HIV-associated dementia [HAD, n=14]). No significant
differences were observed in age, education, or socio-demographic
factors between groups stratified by HAND (p=0.570).
Stratifying by cognitive impairment no significant differences
were observed in education levels (p=0.515), reading and
vocabulary scores (p=0.987 and 0.633 respectively). Stratifying
by cognitive performance, the symptomatic impairment group
performed worse in most of the neuropsychological tests
(p,0.005). (Table 1).
HIV-seropositive women characteristics. When the HIV-
seropositive women were grouped by cognitive performance, no
significant differences were observed between groups with regard
to CD4 cell count, plasma viral load, co-infection with Hepatitis C
virus, body mass index (BMI), or toxicology (p.0.05). Significant
differences were observed in nadir CD4 cell counts and CSF viral
loads, with both being higher in the asymptomatic cognitively
impaired group (p=0.044 and 0.041 respectively; Table 2).
Most HIV-seropositive women were using CART, (94%, or 32
of the 34 women). There was no significant difference among
groups with regard to their specific CART regimens. Using the
CNS Penetration Effect (CPE) scale prepared by Dr. Scott
Letendre [4], we observed no differences in CPE among groups
(Table 2).
Blood sample preparation. Fresh blood samples were
drawn from each patient and collected in ACD tubes. Plasma
samples were obtained from blood double spun centrifugation at
3556g for 10 minutes at room temperature. A plasma aliquot of
700 mL was used for viral load determination, and aliquots of
500 mL were used to determine changes in soluble and cell-
associated insulin receptor (IR) and IR substrate-1 (IRS-1).
CSF sample preparation. All spinal taps were performed by
the same neurologist (VW) using an atraumatic Sprotte needle.
CSF was centrifuged at 1306g for 10 minutes at 4uC, and cell
pellets and supernatants were separated. Aliquots of supernatant
were stored at 280uC and cell pellets were maintained in liquid
nitrogen. CSF samples tested negative for VDRL.
Soluble insulin receptor full-length (sIR-ab, intact) and
insulin receptor-ectodomain (sIR-a) Assay. Plasma sIR
ectodomain and full-length were assayed as described by The
Soluble Insulin Receptor Study Group [47] using an anti-IR
ectodomain antibody (1:1000) (Abcam, Cambridge, MA) for
Table 1. HIV-seropositive women neuropsychological performance.
Normal
Cognition (n=11)
Asymptomatic
impairment (n=8)
Symptomatic
impairment (n=15) p-value
a
bEducation, years 13.3(14.1) 12, 16 12.8(2.1) 9, 16 12.3(2.5) 9, 16 0.515
Reading scores 27.7(2.8) 21, 30 27.9(2.0) 23, 29 28.1(1.7) 25, 30 0.987
Vocabulary scores 49.9(7.2) 39, 62 46.6(10.5) 33, 62 46.4(15.1) 22, 79 0.633
cTrail Making A test 20.1(1.1) 21.8, 1.3 20.3(0.9) 21.5, 0.9 20.6(0.8) 21.9, 1.2 0.431
Trail Making B test 0.6(0.6) 20.6, 1.4 20.3(1.3) 23.1, 1.0 20.7(1.4) 23.9, 1.1 0.015*
Symbol Digit Modality Test 0.0(1.0) 21.3, 1.6 20.9(0.7) 22.1, 0.1 21.3(0.6) 22.5, 20.2 0.005*
Grooved Pegboard dominant hand 0.2(0.5) 20.7, 0.8 21.6(2.1) 25.8, 0.5 20.3(0.6) 21.7, 0.6 0.039*
Grooved Pegboard non dominant hand 0.3(1.0) 21.9, 1.4 22.9(3.1) 28.1, 0.8 20.2(1.0) 22.2, 1.5 0.014*
Stroop color-word 0.2(1.0) 21.6, 1.5 20.5(1.3) 22.6, 1.5 21.5(1.5) 24.3, 0.9 0.013*
dRAVLT recognition 0.8(0.7) 20.9, 1.2 20.1(0.8) 21.3, 1.2 20.5(0.9) 22.2, 0.7 0.001*
RAVLT delay recall 0.4(0.9) 20.9, 1.8 20.3(0.9) 21.6, 0.8 20.7(1.0) 21.9, 1.1 0.028*
RAVLT trial 5 0.2(0.8) 21.0, 1.1 20.7(0.8) 21.7, 0.4 20.6(1.0) 22.4, 0.8 0.037*
Visual Reaction Time non dominant hand 0.3(0.8) 20.8, 1.5 0.9(0.9) 20.6, 1.8 20.2(1.3) 23.0, 2.4 0.094
Auditory Reaction Time non dominant hand 0.3(0.4) 20.5, 0.9 0.3(0.4) 20.5, 0.8 20.3(0.8) 22.8, 0.7 0.042*
Cube Copy 20.3(1.1) 22.0, 0.9 20.8(1.0) 22.0, 0.9 20.6(0.6) 22.0, 20.1 0.617
fNPZ 0.3(0.4) 20.5, 1.0 20.6(0.5) 21.4, 0.0 20.7(0.4) 21.7, 20.1 ,0.001*
gFrontal Executive Domain 0.4(0.6) 20.5, 1.4 20.4(0.9) 21.5, 0.9 21.1(1.2) 23.7, 1.0 0.002*
Psychomotor Speed Domain 0.2(0.5) 20.6, 0.9 0.1(0.5) 20.7, 0.7 0.7(0.7) 22.5, 0.1 0.006*
Verbal Memory Domain 0.5(0.7) 20.9, 1.4 20.4(0.6) 21.5, 0.3 20.6(0.8) 22.0, 0.8 0.005*
Motor Speed Domain 0.1(0.7) 20.9, 1.1 21.6(1.4) 24.4, 0.1 20.4(0.6) 21.4, 0.7 0.007*
asignificant p value,0.05
*,
bmean(SD), range,
cz-scores, mean(SD), range,
dRAVLT=Rey Auditory Verbal Learning Test,
fNPZ=average of the z-scores of all tests,
gcognitive domains.
doi:10.1371/journal.pone.0037358.t001
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Cambridge, MA). Samples were analyzed in a Cytofluor 4000
(Applied Byosystems, CA) using 485/530 nm excitation/emission
filters.
Membrane-bound insulin receptor (mIR) levels, IRS-1
levels and IRS-1 tyrosine phosphorylation. In a subgroup of
the patients described above (23 stratified by HAND into 7 women
with normal cognition, 7 with asymptomatic impairment, and 9
with symptomatic impairment), we analyzed mIR levels, IRS-1
levels, and IRS-1 tyrosine phosphorylation in CSF cell pellets (5
per HAND group). For determination of mIR levels, pellets
(1610
6cells) were incubated with anti-IR-PE antibody (BD
biosciences, CA) for 1 hour at 4uC. For detection of intracellular
IRS-1 levels and phosphorylation, pellets (1610
6 cells) were
permeabilized using the BD Cytofix\Cytoperm Kit (BD biosci-
ences, CA), incubated with anti-IRS-1 or anti-phospho-IRS-1-
tyrosine (pTyr
896) antibodies (Abcam, Cambridge, MA) (1:1000)
for 1 h at 4uC, and finally stained with FITC-secondary antibody
(1:200) for 1 h at 4uC. Samples were analyzed by flow cytometry.
Flow cytometry. All flow cytometric analysis was carried out
using a FACSCalibur cytometer (BD Biosciences, CA). The Cell
Quest software (BD Biosciences, CA) was used for data acquisition
and multivariate analysis. Cells were gated in forward/side scatter
dot plots and FITC or PE emission were measured in the FL1
(band pass filter 525 nm) or FL2 (band pass filter 585 nm)
channels. Data on scatter parameters and histograms were
acquired in log mode. Ten thousand events were evaluated for
each sample and the median peak channel obtained from the
histograms was used to determine levels of mIR, IRS-1, and IRS-1
tyrosine phosphorylation.
Determination of plasma TNF-alpha. We also determined
plasma tumor necrotic factor alpha (TNF-a) levels, as these have
been associated with decreased IRS-1 phosphorylation [48].
Plasma TNF-alpha levels were measured using available ELISA
kits (R & D Systems) following the manufacturer’s instructions.
This assay detects the total amount of TNF-a in samples, which is
the amount of free TNF-a plus the amount of TNF-a bound to
soluble receptor. In brief, 200 mL of each sample, standards, and
positive and negative controls were loaded into wells of a 96 well-
plate containing antibody against human TNF-a. After addition of
reagents, incubations and washes, the optical density of each well
was measured using a microplate reader set to 490 nm. All
samples were analyzed in triplicate and measurements repeated
twice. Standard curves were run in duplicate in each assay. Mean
values were obtained for each plasma sample, and means and SD
were calculated for each group at each time interval. Differences
were analyzed by ANOVA.
Statistical analyses
The study was conducted to assess the association between
soluble and cell-associated insulin receptor dysfunction and
presence or severity of HAND. To achieve this, we compared
soluble insulin receptor levels (MFI) (sIR-a and sIR-ab) in plasma
and CSF between four groups: control and HIV-seropositive
women stratified by cognitive impairment into normal cognition,
asymptomatic impairment, and symptomatic impairment. Because
the data was not normally distributed, these comparisons were
made using non-parametric Kruskal-Wallis test. Using a similar
statistical technique, we compared membrane insulin receptor
(mIR), insulin receptor substrate 1 (IRS-1), and IRS-1 tyrosine
phosphorylation levels in CSF white cell pellets of HIV-
seropositive women stratified by HAND.
The control group consisted of 5 plasma and 5 CSF samples as
described earlier. The use of 5 control samples was adequate to
estimate the median and interquartile range.
All statistical analyses were performed with SAS version 8.02
(SAS Institute, Cary NC) and Intercooled Stata version 8 (Stata
Corp, College Station, TX).
Results
Soluble insulin receptor (sIR) full- length (intact, ab
subunit) and sIR ectodomain (a subunit) levels in plasma
and CSF of HIV-seropositive women
Full-length sIR levels in the plasma and CSF of HIV-
seropositive women were significantly increased relative to controls
(p,0.001 and p=0.003, respectively, Figure 1). When HIV-
seropositive women were stratified by HAND, higher levels of
plasma full-length sIR (intact, ab) were associated with the
Table 2. HIV-seropositive women characteristics.
Normal
Cognition (n=11)
Asymptomatic
impairment (n=8)
Symptomatic
impairment (n=15) p-value
a
Age, years 44.0 (39.0, 47.0) 42.0 (35.5, 44.5) 43.0 (41.0, 48.0) 0.570
bCD4 cells/mm
3 397.0 (275.0, 459.0) 521.0 (346.5, 720.5) 423.0 (291.0, 613.0) 0.503
CD4 nadir cells/mm
3 177.0 (14.0, 384.0) 439.0 (292.0, 513.4) 191.0 (111.0, 391.0) 0.044
*
CSF HIV RNA (log) 1.7 (1.7, 1.7) Detected in 2/9 2.2 (1.7, 2.3) Detected in 4/6 1.7 (1.7, 1.7) Detected in 1/13 0.041
*
Plasma HIV RNA (log) 1.7 (1.7, 3.3) Detected in 4/9 2.9 (2.1, 3.6) Detected in 5/6 1.7 (1.7, 2.2) Detected in 5/12 0.095
Hepatitis C virus 4/11 0/7 6/14 0.131
cBMI 26.5 (25.6, 27.4) 29.9 (22.7, 39.4) 25.6 (23.1, 28.2) 0.420
Toxicology 0/10 1/8; marijuana 3/15; 1 marijuana & 2 cocaine 0.874
ART 11/11 HAART 2/8 none, 2/8 ART, 4/8 HAART 1/15 ART, 14/15 HAART 0.077
Protease inhibitors 8/11 (72.7%) 5/8 (62.5%) 10/15 (66.6%) 0.893
dCPE 6.0 (4.0, 7.0) 3, 10 6.0 (4.0, 7.0) 2, 9 6.0 (4.0, 8.0) 1, 9 0.528
asignificant p value,0.05
*,
bmedian(interquartile range [25
th and 75
th percentile]),
cBMI=body mass index,
dCPE=CNS penetration Effect [4].
doi:10.1371/journal.pone.0037358.t002
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Table 3). Similar results were observed for CSF sIR-ab levels
(p=0.005 with the presence and p=0.002 with the severity of
HAND) (Figure 2B). No significant differences were observed in
plasma and CSF sIR ectodomain (a) levels.
Membrane-bound insulin receptor (mIR), insulin receptor
substrate-1 (IRS-1), and IRS-1 tyrosine phosphorylation
levels in white blood cells (WBC) from the CSF of HIV-
seropositive women
No significant differences were observed in the mIR and IRS-1
levels of HIV-seropositive women stratified by HAND (p=0.834
and 0.868 respectively). A significant decrease in IRS-1 tyrosine
phosphorylation was observed in HIV-seropositive women with
symptomatic impairment versus those with normal cognition
(p=0.02, Table 4 and Figure 3).
Plasma tumor necrotic factor alpha (TNFa) determination
No association was observed between levels of TNFa and
cognitive performance (p=0.325, data mot shown) and no
correlation was observed between levels of TNFa and levels of
IRS-1 tyrosine phosphorylation (p=0.43, data not shown).
Figure 1. Soluble insulin receptor full-length (sIRab) and HIV. Soluble insulin receptor (sIR) intact or full-length (ab) was measured in plasma
(A) and CSF (B) of HIV-seropositive women (HIV+) (n=34) and controls (HIV2) (n=10, 5 with plasma and different 5 for CSF). The sIR subunits were
determined using an ELISA [47] Significantly higher levels of full-length sIR was observed in HIV-seropositive women in plasma and CSF when
compared with controls (p,0.001 and p=0.003 respectively). (MFI=Median Fluorescence Intensity).
doi:10.1371/journal.pone.0037358.g001
Figure 2. Soluble insulin receptor full-length (sIRab) stratified by HAND. Soluble insulin receptor (sIR) intact or full-length (ab) subunit was
measured by ELISA [47] in plasma (A) and CSF (B) of HIV-seropositive women (HIV+) (n=34) stratified by HAND into normal cognition (n=11),
asymptomatic impairment (n=8), and symptomatic impairment (n=15); and 10 HIV-negative controls (HIV2) (5 plasma were different women from 5
CSF). In plasma (A), levels of full-length sIR were significantly increased from controls in all HIV-seropositive women and it correlated with the severity
of HAND (normal cognition [p=0.003], asymptomatic impairment [p,0.001], and symptomatic impairment [p,0.001]). Also, women with
symptomatic impairment had significant higher levels of full-length sIR when compared to those with normal cognition (p=0.009). A similar trend
was observed in CSF samples (B), although the only significant increased was observed in the women with symptomatic impairment when compared
to controls. (MFI=Median Fluorescence Intensity).
doi:10.1371/journal.pone.0037358.g002
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While the prevalence of severe HAND has decreased in the
CART era, that of the milder forms has increased, and cognitive
deterioration and neuropathological changes progress despite viral
suppression and curtailment of immunosuppression by CART
[5,8,49,50,51,52]. These changes could result from inadequate
penetration of CART and residual infection in the brain, chronic
CNS inflammatory and oxidative stress responses, and/or
neurotoxic effects of long-term CART treatment [52,53,54]. Even
with advances in HIV treatment and increased patient survival,
the presence of HAND is associated with increased morbidity and
mortality [1,55]. Hence, there is an imperative need to understand
the pathophysiology of HAND and identify new biomarkers for
HAND [9,10,32,50].
The Soluble Insulin Receptor Study Group designed a method
to determine plasma levels of two forms of the soluble insulin
receptor: ectodomain (a) and full-length or intact protein (ab).
They found that patients with diabetes type 1 had significantly
increased levels of the ectodomain, but not the full-length sIR [47].
They proposed the use of the sIR ectodomain as biomarker for
hyperglycemic states. In contrast, our data suggest that levels of
full-length sIR in plasma could be associated with asymptomatic
glucose derangements in HIV-seropositive women using CART.
In diabetes type 1, sIR ectodomain (a) is likely to occur due to the
cleavage of the ectodomain of the receptor from cell surfaces [47].
In contrast, the appearance of intact or full-length sIR in plasma
probably occurs by a different mechanism, such as release from
damages tissues or mechanisms akin to the generation of soluble
cytokine receptors [56,57].
Several cohort studies observed an association between insulin
resistance, diabetes, and metabolic syndrome in HIV-seropositive
individuals whose CART regimen included protease inhibitors
[14,15,58,59,60]. However those cohorts were composed mostly of
men, and studies of cohorts of women have produced conflicting
findings [61,62,63,64]. In this study, we observed no associations
between the use of CART, use of protease inhibitors, or the CPE
with either IR dysfunction or HAND. Hence, there is a need to
study this issue further in women, and identify factors that could
contribute to the development of insulin resistance in HIV-
seropositive women, such as IR dysfunction.
We observed a significant positive association between full-
length sIR levels and the presence and severity of HAND in a
cohort of HIV-seropositive women without history of abnormal
glucose metabolism. These findings may suggest that asymptom-
atic glucose abnormalities as determined by a significant decrease
in IRS-1 tyrosine phosphorylation may impact cognitive function
in HIV-seropositive women [65,66].
The brain is no longer considered an insulin-insensitive organ.
It has been shown that insulin crosses the blood brain barrier
(BBB) and that insulin receptors are widely distributed in the
brain. Brain IRs are found on both astrocytes and neurons
[22,23,24], and in the human brain, the highest density of IR is
found in the hippocampus and cerebral cortex [22]. Insulin
receptor and the type 1 insulin-like growth factor receptor have
been shown to have essential roles in energy homeostasis, neuronal
growth and survival, and synaptic plasticity (Reviewed in
[20,22,23,24]). A difference has been observed between brain
and peripheral IRs, with the brain IR having smaller alpha (a)
subunit [22,24]. However, once the brain IR is activated by insulin
the signaling effects are the same as in the periphery. Hence, its
activation will mediate insulin-induced glucose transport into
neurons and activate the signal-transduction pathway for energy
production and protein synthesis [22].
We observed a significant increase in levels of CSF sIR in
women with HAND. sIR in the CSF which may be generated by
several mechanisms, including secretion from astrocytes, neurons,
Table 3. Soluble Insulin Receptor Levels (MFI) and HIV-seropositive women stratified by HAND.
sIR levels (MFI)
a
Control (n=10) (5/
group)
Normal cognition
(n=11)
Asymptomatic impairment
(n=8)
Symptomatic impairment
(n=15) p value
b
Plasma sIRab 9296 (9230, 9307) 9900 (9707, 9989) 10181 (9844.5, 10373) 10510 (10330, 10649) ,0.001
*
Plasma sIRa 10291 (9880, 10301) 9746 (9154, 10189) 9920.5 (9435, 10391) 10195 (9477, 10657) 0.599
CSF sIRab 9024 (8637, 9237) 9921 (9353, 9977) 9846 (9286, 10115) 10327 (9780, 11361) 0.005
*
CSF sIRa 9473 (9291, 10165) 9758 (9267, 10058) 9746 (9230, 9987) 9786 (9423, 9961) 0.973
aMFI = Median Fluorescence Intensity; median (interquartile range [25
th and 75
th percentile]),
bsignificant p value,0.05
*.
doi:10.1371/journal.pone.0037358.t003
Table 4. Membrane insulin receptor (mIR), insulin receptor substrate 1 (IRS-1), and IRS-1 tyrosine phosphorylation levels in the CSF
white cell pellet (CSF WCP) stratified by HAND.
CSF WCP
a Normal cognition (n=11)
Asymptomatic
impairment (n=8)
Symptomatic
impairment (n=15) p value
b
mIR (MFI)
c 7.42 (5.71, 9.93) 8.06 (7.64, 9.14) 8.10 (6.32, 10.84) 0.834
IRS-1 15.82 (14.86, 25.48) 18.11 (17.00, 20.54) 17.78 (16.55, 20.44) 0.868
IRS-1 tyrosine phosphorylation 10.75 (9.82, 12.55) 9.47 (8.66, 10.84) 7.37 (6.10, 7.37) 0.027
*
aFor the mIR (MFI) and IRS-1 we analyzed 11 women with normal cognition, 8 with asymptomatic impairment, and 15 with symptomatic impairment. For IRS-1 tyrosine
phosphorylation 5 women per group were analyzed;
bsignificant p value,0.05
*;
cMFI=Median Fluorescence Intensity; median (interquartile range [25
th and 75
th percentile]).
doi:10.1371/journal.pone.0037358.t004
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that crosses the BBB. In our study CSF sIR levels were similar to
plasma sIR levels, suggesting a passive transfer from the blood.
However, we can not exclude the possibility of brain IR
contribution.
This retrospective study has some limitations. First, we assessed
sIR but not blood sugar metabolism (e.g., by the oral glucose
tolerance test, glycosylated hemoglobin assay, or homeostasis
model assessment). However, the observation of decreased IRS-1
tyrosine phosphorylation is consistent with insulin resistance
[65,66]. Second, when determining HAND using a reference
control group for normative purposes, we observed a significant
difference in age between HIV-seropositive women and controls
(p=0.001), with the reference control group being younger. That
finding raised the possibility that increased age might contribute to
the increased level of cognitive impairment seen in the HIV-
seropositive group. However, when the HIV-seropositive group
was stratified by the presence of HAND, there was no significant
association of age with degree of cognitive impairment. If the
observed cognitive impairment in the HIV-seropositive women
was due to the younger reference group (controls for NP z-scores),
this effect should be similar across HAND groups and therefore
should not alter the sIR study results. It should be noted that the
sIR study control group was relatively small (consisting of 5 plasma
and 5 CSF samples). Nonetheless, the use of 5 control samples was
adequate to estimate the median and interquartile range.
This study provides evidence that IR secretion is increased in
HIV-seropositive women, and increased IR secretion is associated
with cognitive impairment in these women. Our findings suggest
that full-length sIR in plasma could be associated with asymp-
tomatic glucose derangements in HIV-seropositive women using
CART and is a contributing factor in the development and
progression of HAND. Since early intervention may help prevent
the progression from mild to more severe forms of HAND, it is
vital to identify an easily measurable and reliable biomarker for
HAND. Full-length sIR may serve as a blood biomarker for the
presence and severity of HAND.
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